相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment
Felicitas Hitz et al.
ANNALS OF HEMATOLOGY (2015)
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D. Jacobsen et al.
BLOOD (2015)
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
David W. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Vincent Ribrag et al.
CLINICAL CANCER RESEARCH (2014)
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
Nicolas Mounier et al.
HAEMATOLOGICA (2013)
The Impact of MYC Rearrangements and Double Hit Abnormalities in Diffuse Large B-Cell Lymphoma
Pei Lin et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
Carsten Mueller et al.
BLOOD (2012)
Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Veronique Blanc et al.
CLINICAL CANCER RESEARCH (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Transformation of Indolent B-Cell Lymphomas
Silvia Montoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma
Helene Blasco et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2009)
How I treat patients with diffuse large B-cell lymphorna
James O. Armitage
BLOOD (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
分享论文
